You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MMR-Proficient Colorectal Cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Colorectal Tumors, Microsatellite Instability Trial in Milano, Rozzano (temozolomide (induction),, pembrolizumab (treatment))

Recruiting
  • Colorectal Neoplasms
  • Microsatellite Instability
  • temozolomide (induction),
  • pembrolizumab (treatment)
  • Milano, Italy
  • +3 more
Sep 28, 2022

Colorectal Cancer, Liver Metastases, MSS Trial (Sinti+Rego+Cele)

Not yet recruiting
  • Colorectal Cancer
  • +2 more
  • (no location specified)
Jul 3, 2023

Metastatic Colorectal Cancer Trial in Baltimore (CY, GVAX, Pembrolizumab)

Completed
Has Results
  • Metastatic Colorectal Cancer
  • Baltimore, Maryland
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Feb 8, 2021

Colorectal Cancer Trial (TMZ, Nivolumab)

Withdrawn
  • Colorectal Cancer
  • (no location specified)
Dec 10, 2019

Tumor Budding in Colorectal Cancer Under Different MMR Status

Completed
  • Tumor Budding
  • Rectal Cancer
  • total mesorectal exicision
  • Guangzhou, Guangdong, China
    Department of colorectal surgery, the Sixth Affiliated Hospital,
Nov 8, 2022

Metastatic Colorectal Cancer Trial in Køge (Irreversible electroporation, Calcium electroporation, Pembrolizumab)

Recruiting
  • Metastatic Colorectal Cancer
  • Irreversible electroporation
  • +2 more
  • Køge, Denmark
    Zealand University Hospital
Jan 27, 2023

Colorectal Cancer Trial in Essen (Atezolizumab)

Recruiting
  • Colorectal Cancer
  • Essen, Germany
    Westdeutsches Tumorzentrum
Feb 14, 2022

Refractory Metastatic Colorectal Cancer, pMMR, MSS Trial in United States (RP2, RP3, atezolizumab)

Not yet recruiting
  • Refractory Metastatic Colorectal Cancer
  • +2 more
  • RP2
  • +3 more
  • Los Angeles, California
  • +5 more
Feb 24, 2023

Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer Trial in Australia, China

Recruiting
  • Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
  • Benowa, Queensland, Australia
  • +7 more
Jan 30, 2023

Pancreatic Cancer Metastatic, Colorectal Cancer Metastatic Trial in Baltimore (Neoantigen Vaccine with Poly-ICLC adjuvant,

Not yet recruiting
  • Pancreatic Cancer Metastatic
  • Colorectal Cancer Metastatic
  • Baltimore, Maryland
    Sidney Kimmel Comprehensive Cancer Center
Aug 5, 2022

Anal Squamous Cell Carcinoma, Colorectal Tumors, Soft Tissue Sarcoma Trial (Regorafenib in combination with Tislelizumab)

Not yet recruiting
  • Anal Squamous Cell Carcinoma
  • +7 more
  • Regorafenib in combination with Tislelizumab
  • (no location specified)
Oct 12, 2022

Neoadjuvant Chemotherapy and Immunotherapy for HER2(-),pMMR

Recruiting
  • Gastric Cancer
  • SOX plus Paclitaxel(albumin-bound) followed by PD-1 antibody
  • Beijing, Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Sep 12, 2022

Adenocarcinoma of the Colon Trial in London (Pembrolizumab)

Recruiting
  • Adenocarcinoma of the Colon
  • London, United Kingdom
    University College Hospital
Jul 20, 2022

Refractory Metastatic Colorectal Cancer, Solid Tumor, Metastatic Microsatellite-stable Colorectal Cancer Trial in Milano

Recruiting
  • Refractory Metastatic Colorectal Cancer
  • +3 more
  • Milano, MI, Italy
    Istituto Nazionale dei Tumori
Jan 24, 2022

Mismatch Repair-proficient, Colorectal Cancer Metastatic, Microsatellite Stable Trial in Hangzhou (Tislelizumab, Irinotecan,

Recruiting
  • Mismatch Repair-proficient
  • +2 more
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Dec 17, 2021

MSS, pMMR, Metastatic Colorectal Adenocarcinoma Trial in Shenyang (TKI ± anti-PD-1 antibody)

Recruiting
  • MSS
  • +2 more
  • TKI ± anti-PD-1 antibody
  • Shenyang, Liaoning, China
    Cancer Hospital of China Medical University/Liaoning Cancer Hosp
Sep 28, 2021

Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H

Recruiting
  • Colorectal Cancer
    • Shanghai, China
      Fudan University Shanghai Cancer Center
    Oct 18, 2023

    Lynch Syndrome Based on Next-generation Sequencing in Colorectal

    Completed
    • Lynch Syndrome
    • next-generation sequencing
    • Fuzhou, Fujian, China
    • +6 more
    Jul 14, 2021

    Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in ZhengZhou (Cadonilimab

    Not yet recruiting
    • Colorectal Cancer
    • +3 more
    • Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody
    • ZhengZhou, Henan, China
      Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
    Jun 18, 2023

    Prostatic Tumor, Prostate Cancer, BRCA2 Mutation Trial in Boston (Prostate cancer screening)

    Recruiting
    • Prostatic Neoplasm
    • +7 more
    • Prostate cancer screening
    • Boston, Massachusetts
      Massachusetts General Hospital
    Nov 30, 2021

    Colorectal Cancer Not MSI-H or MMR-deficient, GIST, Oesophageal or Gastric Carcinoma Trial in France (Phase 1 : Regorafenib,

    Recruiting
    • Colorectal Cancer Not MSI-H or MMR-deficient
    • +9 more
    • Phase 1 : Regorafenib
    • +4 more
    • Bordeaux, France
    • +6 more
    Dec 6, 2021

    Microsatellite Unstable Colorectal Cancer, Microsatellite Stable Colorectal Cancer, Mismatch Repair Proficient Colorectal Cancer

    Active, not recruiting
    • Microsatellite Unstable Colorectal Cancer
    • +3 more
    • Gilbert, Arizona
    • +31 more
    Dec 21, 2021

    The mCRC pMMR/MSS or dMMR/MSI-H Status Received Palliative

    Completed
    • Colorectal Cancer Metastatic
    • +2 more
      • Guangzhou, Guangdong, China
        Sun yat-sen university cancer center
      Jul 23, 2020

      Colorectal Carcinoma Trial in Spain (Avelumab)

      Completed
      • Colorectal Carcinoma
      • Barcelona, Spain
      • +7 more
      Oct 5, 2020

      Metastatic Colorectal Cancer Trial in Milan (Temozolomide, Nivolumab, Ipilimumab)

      Completed
      • Metastatic Colorectal Cancer
      • Milan, MI, Italy
        Fondazione IRCCS Istituto Nazionale dei Tumori
      Apr 1, 2022